Chugai Seiyaku KK

4519

Equity

ISIN JP3519400000 / Valor 761611

Tokyo Stock Exchange (2024-12-27)

JPY 7,105.00+2.29%

Chugai Seiyaku KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Chugai Seiyaku KK is a research-based pharmaceutical company that specializes in the development, production, and marketing of prescription medicines, with a strong focus on biopharmaceuticals and molecular targeted therapies. The company emphasizes the importance of safety and regulatory compliance, having established an independent Drug Safety Division to ensure the secure and appropriate use of its products globally. Chugai's Quality & Regulatory Compliance Unit oversees the adherence to pharmaceutical regulations and maintains the integrity of its quality management system through rigorous audits and a global IT system. The company prioritizes high-value R&D projects and actively secures intellectual property rights, including lifecycle patents and innovative drug discovery technologies. Chugai collaborates closely with the Roche Group for global co-development, aiming to bring innovative medicines to market efficiently and effectively.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the third quarter of FY2024, Chugai Seiyaku KK reported a revenue of ¥868.5 billion, marking a 3.7% increase compared to the same period last year. This growth was primarily driven by an increase in other revenue, despite sales remaining relatively stable.

Operating and Net Income

Chugai Seiyaku KK's operating profit for the nine months ending in Q3 FY2024 was ¥418.6 billion, reflecting a significant 31.8% year-on-year increase. Net income also saw a substantial rise, reaching ¥295.8 billion, which is a 26.2% increase from the previous year.

Core Results

The core results for Chugai Seiyaku KK in FY2024 Q3 showed a revenue of ¥868.5 billion, with sales contributing ¥750.3 billion. The core operating profit was reported at ¥426.6 billion, a 25.3% increase year-on-year, while core net income rose by 20.4% to ¥301.3 billion.

Revised Forecasts

Chugai Seiyaku KK revised its full-year forecasts for FY2024, increasing the revenue projection to ¥1,150.0 billion, up by ¥80.0 billion from the original forecast. The core operating profit forecast was also raised to ¥540.0 billion, reflecting a 17.4% increase from the initial estimate.

Dividend Outlook

The year-end dividend forecast for Chugai Seiyaku KK remains undecided due to significant changes in the business environment. The company aims for a consolidated dividend payout ratio of 45% on average, based on Core EPS, to ensure stable profit distribution to shareholders.

Summarized from source with an LLMView Source

Key figures

32.0%1Y

89.6%3Y

110%5Y

Performance

34.3%1Y

31.7%3Y

30.3%5Y

Volatility